ЎСМА КАСАЛЛИКЛАРИДА ДЕПРЕССИЯ ВА ХАВОТИРЛИ ХОЛАТЛАРНИ ДАВОЛАШГА ЗАМОНАВИЙ ЁНДАШУВЛАР.
Keywords:
Калит сўзлар: психоонкология , психофармакотерапия , саратон билан боғлиқ аломатлар , паллиатив ёрдам , ҳаёт сифати , онкологияAbstract
Резюме:Саратон касаллиги билан оғриган беморларнинг камида 25-30 фоизи руҳий бузилишлардан азият чекмоқда, шунинг учун психотроп дорилар онкологияда узоқ вақтдан бери муваффақиятли қўлланилган. Психофармакологик препаратлар саратоннинг ўзи ва терапиянинг ножўя таъсирлари (уйқунинг бузилиши, иштаҳани йўқотиш, оғриқ, кўнгил айниши, чарчоқ ва бошқалар) билан боғлиқ аломатлар учун асосий ёки ёрдамчи даволаш сифатида ҳам қўлланилади. Психотроп препаратларни қўллаш беморларнинг ҳаёт сифатига салбий таъсир кўрсатадиган аломатларни нишонга олиш имконини беради. Бироқ, психотроп препаратларни буюришда дори воситаларининг ўзаро таъсири ва ён таъсири билан боғлиқ муаммолар мавжуд.
References
1. Ромасенко В.А., Скворцов К.А. Нервно-психические нарушения при раке. М.; 1961.
2. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Психические расстройства в онкологии (результаты мультицентровой программы "Синтез"). Психические расстройства в общей медицине. 2009; 1: 4—11.
5. Барденштейн Л.М., Вельшер Л.З., Аверьянова С.В. Психологические особенности больных раком молочной железы как прогностический фактор. Российский медицинский журнал. 2011; 5: 13—7.
11. Зотов П.Б., Уманский С.М., Ганцев Ш.Х. Суицидальные действия больных злокачественными новообразованиями. Сибирский вестник психиатрии и наркологии. 2005; 2: 99—101.
41. Самушия М.А., Мустафина Е.А. Нозогении (психогенные реакции) у женщин со злокачественными опухолями органов репродуктивной системы. Психические расстройства в общей медицине. 2007; 2(3): 11—6.
42. Резник А.М., Миронычев Г.Н., Арбузов А.Л., Дзюба К.В., Назаралиева А.А. Применение ципрамила при депрессии у больных с онкологическими заболеваниями желудочно-кишечного тракта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004; 104(9): 39—42.
56. Бажин Е.Ф., Гнездилов А.В. Психофармакологические и психокоррекционные аспекты реабилитации онкологических больных. Журнал клинической психоонкологии. 2003; 3: 18—23.
REFERENCES 1. Romasenko V.A., Skvortsov K.A. Nervous and Psychic Disorders in Cancer Patient. Moscow; 1961. (in Russian)
2. Smulevich A.B., Andryushchenko A.V., Beskova D.A. Psychic disorders in oncology (results of the multicenter program "Synthesis"). Psikhicheskie Rasstroystva v Obshchey Meditsine. 2009; 1: 4—11. (in Russian)
3. Wein S., Sulkes A., Stemmer S. The oncologist s role in managing depression, anxiety, and demoralization with advanced cancer. Cancer J. 2010; 16(5): 493—9. 4. Pasquini M., Biondi M., Costantini A., Cairoli F., Ferrarese G., Picardi A. et al. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary fi ndings from a liaison service in an oncology division. Depress. Anxiety. 2006; 23(7): 441—8.
5. Bardenshteyn L.M., Vel'sher L.Z., Aver'yanova S.V. Psycholofi ical features of patients with breast cancer as predictive factor. Rossiyskiy Meditsinskiy Zhurnal. 2011; 5: 13—7. (in Russian)
6. Onitilo A.A., Nietert P.J., Egede L.E. Effect of depression on allcause mortality i adults with cancer and differential effects by cancer site. Gen. Hosp. Psychiatry. 2006; 28(5): 396—402.
7. Brintzenhofe-Szoc К.М., Levin Т.Т., Li К., Kissane D.W., Zabora J.R. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009; 50(4): 383—91.
8. Rhondali W., Perceau E., Berthiller J., Saltel P., Trillet-Lenoir V., Tredan O. et al. Frequency of depression among oncology outpatients and association with other symptoms. Support. Care Cancer. 2012; 20(11): 2795—802.
9. Delgado-Guay M., Parsons H., Li Z., Palmer J., Bruera E. Symptom distress in advanced cancer patients with anxiety and depression in a palliative care setting. Support. Care Cancer. 2009; 17(5): 573—9.
10. Yu L.S., Chojniak R., Borba M. A., Girão D. S., Lonrenço M. T. Prevalence of anxiety in patients awaiting diagnostic procedures in an oncology center in Brazil. Psychooncology. 2011; 20(11): 1242—5.
11. Zotov P.B., Umanskiy S.М., Gantsev Sh.Kh. Suicide actions of patients with malignant tumors. Sibirskiy Vestnik Psikhiatrii i Narkologii. 2005; 2: 99—101. (in Russian)
12. Laoutidis Z.G., Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013; 13: 140—8.
13. Baillet F. The organization of psycho-oncology. Cancer Radiother. 2002; 6(Suppl 1): 214s—8s.
14. Breitbart W., Poppito S., Rosenfeld B., Vickers A. J., Li Y., Abbey J. et al. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J. Clin. Oncol. 2012; 30(12): 1304—9.
15. Akizuki N. The role of psycho-oncology in cancer care in Japan. Seishin Shinkeigaku Zasshi. 2010; 112(12): 1210—5.
16. Travado L., Grassi L., Gil F.,Ventura C., Martins C. Southern European Psycho-Oncology Study Group. Physician-patient communication among Southern European cancer physicians: the infl uence of psychosocial orientation and burnout. Psychooncology. 2005; 14: 661—70.
17. Passik S.D., Dugan W., McDonald M.V., Rosenfeld B., Theobald D.E., Edgerton S. Oncologists' recognition of depression in their patients with cancer. J. Clin. Oncol. 1998; 16(4): 1594—600.
18. Patrick D.L., Ferketich S.L., Frame P.S., Harris J.J., Hendricks C.B., Levin B. et al. National Institutes of Health State-of-the-Science Panel. Management in Cancer: Pain, Depression, and Fatigue. J. Natl. Cancer Inst. 2003; 95(15): 1110—7.
19. Yeh M.L., Chung Y.C., Hsu M.Y., Hsu C.C. Quantifying psychological distress among cancer patients in interventions and scales: a systematic review. Curr. Pain Headache Rep. 2014; 8(3): 399.
20. Vodermaier A., Linden W., Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J. Natl. Cancer Inst. 2009; 101(21): 1464—88.
21. Mitchell A.J. Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis. J. Natl. Compr. Canc. Netw. 2010; 8(4): 487—94.
22. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67(6): 361—70.
23. Mackenzie L.J., Carey M.L., Sanson-Fisher R.W., D'Este C.A., Paul C.L., Yoong S.L. Agreement between HADS classifi cations and single-item screening questions for anxiety and depression: a cross-sectional survey of cancer patients. Ann. Oncol. 2014; 25(4): 889—95.
24. Quill T.E., Arnold R.M., Platt F. "I wish things were different": expressing wishes in response to loss, futility, and unrealistic hopes. Ann. Intern. Med. 2001; 135: 551—5.
25. Husson O., Mols F., van de Poll-Franse L.V. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann. Oncol. 2011; 22(4): 761—72.
26. Caruso R., Grass L., Nanni M.G., Riba M. et al. Psychopharmacology in psychooncology. Сurr. Psychiatry Rep. 2013; 15(9): 393.
27. Hardly J.R., O'Shea A., White C., Gilshenan K., Welch L., Douglas C. The effi cacy of haloperidol in the management of nausea and vomiting in patients with cancer. J. Pain Symptom Manage. 2010; 40(1): 111—6.
28. Vig S., Seibert L., Green M.R. Olanzapine is effective for refractory chemotherapyinduced nausea and vomiting irrespective of chemotherapy emetogenicity. J. Cancer Res. Clin. Oncol. 2014; 140(1): 77—82.
29. Razavi D., Delvaux N., Farvacques C., De Brier F., Van Heer C., Kaufman L. et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J. Clin. Oncol. 1993; 11(7): 1384—90.
30. Malik I.A., Khan W.A., Qazilbash М., Ata E., Butt A., Khan M.A. Clinical effi cacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am. J. Clin. Oncol. 1995; 18(2): 170—5.
31. Holland J.C., Romano S.J., Heiligenstein J.H., Tepner R.G., Wilson M.G. A controlled trial of fl uoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998; 13: 291—300
32. Larid B., Colvin L., Fallon M. Management of cancer pain: basic princ iples and neuropathic cancer pain. Eur. J. Cancer. 2008; 44(8): 1078—82.
33. Saarto T., Wiffen P. J. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 2007; 17(4): CD005454.
34. Amr Y.M., Yousef A.A. Evaluation of effi cacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J. Pain. 2010; 26(5): 381—5
35. Rodriguez Vega S., Palao A., Torres G., Hospital A., Benito G., Pérez E. et al. Combined therapy versus usual care for the treatment of depression in oncologic patients: a randomized controlled trial. Psychooncology. 2011; 20(9): 943—52
36. Arimochi H., Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur. J. Pharmacol. 2006; 541(1—2): 17—23.
37. Jahchcm N.S., Dudley J.Т., Mazur P.К., Flores N., Yang D., Palmerton A. et al. A drug repositioning approach identifi es tricyclic antidepressants as inhibitors of small cell lungcancer and other neuroendocrine tumors. Cancer Discov. 2013; 3(12): 1364—77.
38. Higgins S.C., Pilkington G.J. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res. 2010; 30(2): 391—7.
39. Gil-Ad I., Zolokov A., Lomnitski L., Taler M., Bar М., Luria D. et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancerxenografted mice. Int. J. Oncol. 2008; 33(2): 277—86.
40. Ng C.G., Boks M.P., Zainal N.Z., de Wit N.J. The prevalence and pharmacotherapy of depression in cancer patients. J. Affect. Disord. 2011; 131(1—3): 1—7.
41. Samushiya M.A., Mustafi na E.A. Nosogenic (psychogenic) reactions at women with malignant tumors of reproductive system. Psikhicheskie Rasstroystva v Obshchey Meditsine. 2007; 2(3): 11—6. (in Russian)
42. Reznik A.M., Mironychev G.N., Arbuzov A.L., Dzyuba K.V., Kazaralieva A.A. Application of cipramil for patients with gastrointestinal cancer and depression. Zhumal Nevrologii i Psikhiatrii im. S. S. Korsakova. 2004; 104(9): 39—42. (in Russian)
43. Musselmatin D.L., Somerset W.I., Guo Y., Manatunga A.K., Porter М., Penna S. et al. A double-blind multicenter parallel-group study of paroxetine, desipramine or placebo in breast cancer patients (stages I, II, III, IV) with major depression. J. Clin. Psychiatry. 2006; 13: 288—96.
44. Costa D., Mogos I., Toma T. Effi cacy of mianserin in the treatment of depression of women with cancer. Acta Psychiatr. Scand. 1985; 13(suppl. 320): 85—92.
45. van Heeringen K., Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br. J. Psychiatry. 1996; 169(4): 440—3.
46. Razavi D., Allilaire J.F., Smith М., Salimpour A., Verra М., Desclaux B. et al. The effect of fl uoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr. Scand. 1996; 13: 205—10
. 47. Fisch M.J., Loehrer P.J., Kristeller J., Passik S., Jung S.H., Shen J. et al. Oncology Group Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J. Clin. Oncol. 2003; 21(10): 1937—43.
48. Navari R.M., Brenner M.C., Wilson M.N. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res. Treat. 2008; 13: 197—201.
49. Fisch M. Treatment of depression in cancer. J. Natl. Cancer Inst. Monogr. 2004; (32): 105—11.
50. Evans R.L., Connis R.T. Comparison of brief group therapies for depressed patients receiving radiation treatment. Public Health Rep. 1995; 110(3): 306—11. 51. Kuijer R.G., Buunk B.P., De Jong G.M., Ybema J.F., Sanderman R. Effects of a brief intervention program for patients with cancerand their partners on feelings of inequity, relationship quality and psychological distress. Psychooncology. 2004; 13(5): 321—34.
52. Akechi T., Okuyama T., Onishi J., Morita Т., Furukawa T. A. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst. Rev. 2008; Issue 2: CD005537.
53. Jakuhovits E. Possibilities of hypnosis and hypnosuggestive methods in oncology. Magy. Onkol. 2011; 55(1): 22—31.
54. Spiegel D., Bloom J. K., Kraemer H. C., Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989; 2: 888—91.
55. Küchler Т., Bestmann B., Rappat S., Henne-Bnms P., Wood-Pauphinee S . Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J. Clin. Oncol. 2007; 25(19): 2702—8.
56. Bazhin E.F., Gnezdilov A.V. Psychopharmacological and psychological aspects of rehabilitation of oncological patients. Zhurnal Klinicheskoy Psikhoonkologii. 2003; 3: 18—23. (in Russian)
57. Pothoulaki M., MacDonald R., Flowers P. An interpretative phenomenological analysis of an improvisational music therapy program for cancer patients. J. Music Ther. 2012; 49(1): 45—67.
58. Bradt J., Dileo C., Grocke D., Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Sys. Rev. 2011; 10(8): CD006911.
59. Kovács Z., Szabó C., Fülöp E. The therapy helps — psychosocial support of patients diagnosed with breast-cancer; reducing anxiety and depression. Psychiat. Hung. 2013; 28(4): 454—63.
60. Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J. et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl. J. Med. 2000; 342: 1462—70.
